Document is current
Any future updates will be listed below
-
Authors
Wang, Shanshan
Hu, Ping
Shen, Zewei
Chen, Liming
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 9 December 2025
Accepted: 5 February 2026
First Online: 18 March 2026
Declarations
:
: Ping Hu and Zewei Shen are employees of Novo Nordisk A/S, the sponsors of this study, and Zewei Shen also owns shares in Novo Nordisk A/S. Shanshan Wang and Liming Chen report no conflicts of interest.
: The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices. Patient consent was not required as the analyses used retrospective de-identified data without access to personal identifying information. The study protocol and the application for a waiver to informed consent were approved by the independent ethics committee and institutional review board. We can confirm that we, the authors, have permission to use the Tianjin Healthcare and Medical Big Data Platform to access and use the data for this study.
